Magnitude Biosciences and BioAscent Discovery Announce Collaboration
- 6 days ago
- 1 min read
Magnitude Biosciences and BioAscent Discovery Ltd. are pleased to announce a new research collaboration that will combine Magnitude Biosciences’ VivoScan™ C. elegans whole organism screening platform with BioAscent’s richly annotated Chemogenomics Library to generate high quality phenotypic datasets.
“This collaboration highlights the power of whole-organism screening as a complement to traditional drug discovery approaches,” said Dr Chris Saunter, Director of Magnitude Biosciences. “By combining BioAscent’s Chemogenomics library with VivoScan™’s ability to run large-scale screens in a model of healthy aging, we can apply well-annotated, mechanism-informed compounds directly in a physiologically relevant system. This enables the rapid identification of meaningful biological effects and insights that go well beyond what can be learned from in vitro models alone.”
